<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">evrazkar</journal-id><journal-title-group><journal-title xml:lang="ru">Евразийский Кардиологический Журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Eurasian heart journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2225-1685</issn><issn pub-type="epub">2305-0748</issn><publisher><publisher-name>Евразийская ассоциация кардиологов</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.38109/2225-1685-2020-4-44-49</article-id><article-id custom-type="elpub" pub-id-type="custom">evrazkar-6236</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>ПОВЫШЕНИЕ ПРИВЕРЖЕННОСТИ К ЛЕЧЕНИЮ ВАРФАРИНОМ С ПОМОЩЬЮ ОБУЧАЮЩИХ ПРОГРАММ У БОЛЬНЫХ С МЕРЦАНИЕМ ПРЕДСЕРДИЙ</article-title><trans-title-group xml:lang="en"><trans-title>INCREASED ADHERENCE TO WARFARIN TREATMENT WITH TRAINING PROGRAMS IN PATIENTS WITH ATRIAL FIBRILLATION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0654-5963</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Джишамбаев</surname><given-names>Э. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Djishambaev</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заместитель директора по научной работе, </p><p>720040, г. Бишкек, Кыргызская Республика, ул. Т. Молдо, д.3</p></bio><bio xml:lang="en"><p>Dr. of Sci. (Med.), professor, Deputy Director for scientific work</p><p>720040, Bishkek, Kyrgyz Republic, T. Moldo Street, 3 </p></bio><email xlink:type="simple">ernestDD1958@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1382-3068</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хакимова</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Khakimova</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, стар. науч. сотрудник отделения нарушений ритма сердца</p><p>720040, г. Бишкек, Кыргызская Республика, ул. Т. Молдо, д.3</p></bio><bio xml:lang="en"><p>720040, Bishkek, Kyrgyz Republic, T. Moldo Street, 3 </p></bio><email xlink:type="simple">saodat.f.2011@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9869-0630</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шатенова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Shatenova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>млад. науч. сотрудник отделения нарушений ритма сердца</p><p>720040, г. Бишкек, Кыргызская Республика, ул. Т. Молдо, д.3</p></bio><bio xml:lang="en"><p>720040, Bishkek, Kyrgyz Republic, T. Moldo Street, 3 </p></bio><email xlink:type="simple">ashatenova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1423-9755</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мурзалиева</surname><given-names>Э. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Murzalieva</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>млад. науч. сотрудник отделения нарушений ритма сердца</p><p>720040, г. Бишкек, Кыргызская Республика, ул. Т. Молдо, д.3</p></bio><bio xml:lang="en"><p>720040, Bishkek, Kyrgyz Republic, T. Moldo Street, 3 </p></bio><email xlink:type="simple">murzalieva.erkeaiym@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0467-1664</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Усупбаева</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Usupbaeva</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед.наук, профессор, зав. отд. функциональной диагностики</p><p>720040, г. Бишкек, Кыргызская Республика, ул. Т. Молдо, д.3</p></bio><bio xml:lang="en"><p>720040, Bishkek, Kyrgyz Republic, T. Moldo Street, 3 </p></bio><email xlink:type="simple">d_usupbaeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный центр кардиологии и терапии им. М.М. Миррахимова при Министерстве здравоохранения Кыргызской Республики</institution><country>Кыргызстан</country></aff><aff xml:lang="en"><institution>National Center of Cardiology and Internal Medicine named after M. Mirrakhimov</institution><country>Kyrgyzstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2020</year></pub-date><volume>0</volume><issue>4</issue><fpage>44</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Джишамбаев Э.Д., Хакимова С.И., Шатенова А.М., Мурзалиева Э.Н., Усупбаева Д.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Джишамбаев Э.Д., Хакимова С.И., Шатенова А.М., Мурзалиева Э.Н., Усупбаева Д.А.</copyright-holder><copyright-holder xml:lang="en">Djishambaev E.D., Khakimova S.I., Shatenova A.M., Murzalieva E.N., Usupbaeva D.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.heartj.asia/jour/article/view/6236">https://www.heartj.asia/jour/article/view/6236</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: оценка роли обучающих программ по антикоагулянтной терапии у пациентов с мерцанием предсердий в повышении приверженности к лечению варфарином.</p></sec><sec><title>Материал и методы</title><p>Материал и методы: в исследование включены пациенты с мерцанием предсердий, разделенных на две группы: основную (n=125) – пациенты, прошедшие курс  обучающей программы, и контрольную (n=216), рандомизированную для обычного ухода, обучающие занятия в которой не проводились. Сравниваемые группы были сопоставимы по половому (55,8% мужчин и 44,2% женщин – в основной и 62,4% мужчин (p&lt;0,3) и 37,6% женщин (p&lt;0,3) – в контрольной) и возрастному признаку (64,0±10,4 и 62,0±11,4 лет, соответственно, (p&lt;0,1)). Оценка риска инсульта осуществлялась с помощью шкалы CHA2DS2-VASc.</p></sec><sec><title>Результаты</title><p>Результаты: средний балл по шкале CHA2DS2-VASc в основной группе у мужчин составил 2,4±1,2, у женщин – 3,4±1,2. В контрольной группе у мужчин данный  показатель равнялся 2,5±1,3, у женщин – 3,5±1,2. Хотя количество пациентов,  регулярно принимавших варфарин в основной и контрольной группах существенно не различалось (61,4% и 54,9%, соответственно, р=0,2), число больных, принимавших  пероральные антикоагулянты (варфарин+ривароксабан), в основной группе составило 85,5%, что оказалось достоверно выше данных контрольной группы – 61,5% (р=0,002). Среди пациентов, прошедших обучение, оказалось достоверно больше лиц, регулярноконтролирующих МНО – 80,4% против 44,0% (р=0,005) в контрольной группе. При этом, количество больных, достигших целевого значения МНО, в основной группе также было значимо больше в сравнении с контрольной группой (66,7% против 36,0%, р=0,04).</p></sec><sec><title>Заключение</title><p>Заключение: проведение курса обучающих программ среди пациентов с мерцанием  предсердий повышает приверженность к назначенному лечению варфарином, что  проявляется увеличением количества пациентов, регулярно принимающих препарат и контролирующих МНО, а также существенным увеличением числа больных, достигшихцелевых уровней МНО.  </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study: to assess the role of educational programs on anticoagulant therapy in patients with atrial fibrillation in increasing adherence to warfarin treatment.</p></sec><sec><title>Material and methods</title><p>Material and methods: the study included patients with atrial fibrillation, divided into two groups: the main group (n=125) - patients who completed the training program, and the control group (n=216), randomized for routine care, without training sessions. Comparison of the groups were comparable in sex (55.8% of men and 44.2% of women – in main group and 62.4% of men (p&lt;0.3) and 37.6% (p&lt;0.3) - in the control group) and age (64.0±10.4 and 62.0±11.4 years, respectively, p&lt;0.1). Stroke risk was assessed using the CHA2DS2-VASc scale.</p></sec><sec><title>Results</title><p>Results: the average CHA2DS2-VASc score in the main group was 2.4±1.2 for men and 3.4±1.2 for women. In the control group, this indicator was 2.5±1.3 for men, and 3.5±1.2 for women. Although the number of patients who regularly took warfarin in the main and control groups did not differ significantly (61.4% and 54.9%, respectively, p=0.2), the number of patients who took oral anticoagulants (warfarin + rivaroxaban) in the main group was 85.5%, which turned out to be significantly higher than the data of the control group - 61.5% (p=0.002). Among the patients who underwent training, there were significantly more people who regularly monitor INR, comparing to control group (80.4% versus 44.0%, p=0.005). At the same time, the number of patients who achieved the target INR in the main group was also significantly higher in comparison with the control group (66.7% versus 36.0%, p=0.04).</p></sec><sec><title>Conclusion</title><p>Conclusion: conducting a course of educational programs among patients with atrial fibrillation increases adherence to the prescribed treatment with warfarin. This is manifested by increased number of patients, who regularly take the drug and monitor INR, as well as a significant increased number of patients who have reached the target INR levels.  </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мерцание предсердий</kwd><kwd>антикоагулянтная терапия</kwd><kwd>МНО</kwd><kwd>ишемический инсульт</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>anticoagulant treatment</kwd><kwd>INR</kwd><kwd>ischemic stroke</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Feinberg W.M., Blackshear J.L., Laupacis A. et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch. Intern. Med. 1995; 155: 469-473.</mixed-citation><mixed-citation xml:lang="en">Feinberg W.M., Blackshear J.L., Laupacis A. et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch. Intern. Med. 1995; 155: 469-473.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Amer. J. Cardiol. 2009; 104: 1534–1539. DOI: 10.1016/j.amjcard.2009.07.022</mixed-citation><mixed-citation xml:lang="en">Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Amer. J. Cardiol. 2009; 104: 1534–1539. DOI: 10.1016/j.amjcard.2009.07.022</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Marini C., De Santis F., Sacco S. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a populationbased study. Stroke. 2005; 36 (6): 1115-1119. DOI: 10.1161/01.STR.0000166053.83476.4a.</mixed-citation><mixed-citation xml:lang="en">Marini C., De Santis F., Sacco S. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a populationbased study. Stroke. 2005; 36 (6): 1115-1119. DOI: 10.1161/01.STR.0000166053.83476.4a.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2014; 45: 520–526. DOI: 10.1161/STROKEAHA.113.003433.</mixed-citation><mixed-citation xml:lang="en">Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2014; 45: 520–526. DOI: 10.1161/STROKEAHA.113.003433.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Miyasaka Y., Barnes M.E., Gersh B.J. et al. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke 2005; 36: 2362-2366. https://doi.org/10.1161/01.STR.0000185927.63746.23</mixed-citation><mixed-citation xml:lang="en">Miyasaka Y., Barnes M.E., Gersh B.J. et al. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke 2005; 36: 2362-2366. https://doi.org/10.1161/01.STR.0000185927.63746.23</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Annals of Internal Medicine 2007; 146: 857–8867. DOI:10.7326/0003-4819-146-12-200706190-00007.</mixed-citation><mixed-citation xml:lang="en">Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Annals of Internal Medicine 2007; 146: 857–8867. DOI:10.7326/0003-4819-146-12-200706190-00007.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lip G.Y., Edwards S.J. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thrombosis Research 2006; 118(3): 321–233. DOI: 10.1016/j.thromres.2005.08.007.</mixed-citation><mixed-citation xml:lang="en">Lip G.Y., Edwards S.J. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thrombosis Research 2006; 118(3): 321–233. DOI: 10.1016/j.thromres.2005.08.007.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Gladstone D.J., Bui F., Fang J. et al. Potentially preventable stroke in high risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40: 235-240. DOI: 10.1161/STROKEAHA.108.516344.</mixed-citation><mixed-citation xml:lang="en">Gladstone D.J., Bui F., Fang J. et al. Potentially preventable stroke in high risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40: 235-240. DOI: 10.1161/STROKEAHA.108.516344.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2): 263-272. DOI: 10.1378/chest.09-1584.</mixed-citation><mixed-citation xml:lang="en">Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2): 263-272. DOI: 10.1378/chest.09-1584.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleedingin patients with atrial fibrillation: The Euro Heart Survey // Chest. 2010; 138 (5):1093. DOI:10.1378/chest.10-0134.</mixed-citation><mixed-citation xml:lang="en">Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleedingin patients with atrial fibrillation: The Euro Heart Survey // Chest. 2010; 138 (5):1093. DOI:10.1378/chest.10-0134.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">European Health for All database (HFA-DB). World Health Organization, 2014. http://data.euro.who.int/nfabd/.</mixed-citation><mixed-citation xml:lang="en">European Health for All database (HFA-DB). World Health Organization, 2014. http://data.euro.who.int/nfabd/.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Тургумбаева Ж.Д., Акынбеков К.У., Тургумбаев Д.Д. Структура заболеваемости и факторы риска мозгового инсульта в г. Бишкек по данным регистра. Вестник КазНМУ 2015; (3): 92-96.</mixed-citation><mixed-citation xml:lang="en">Turgumbaeva J.D., Akynbekov K.U., Turgumbaev D.D. The structure of the incidence and risk factors of stroke in Bishkek according to the register. Vestnik KazNMU 2015; (3): 92-96. (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Macedo A.F., Bell J., McCarron C. et al. Determinants of Oral Anticoagulation Control in New Warfarin Patients: Analysis Using Data From Clinical Practice Research Datalink. Thromb. Res. 2015; 136 (2): 250-260. DOI: 10.1016/j.thromres.2015.06.007.</mixed-citation><mixed-citation xml:lang="en">Macedo A.F., Bell J., McCarron C. et al. Determinants of Oral Anticoagulation Control in New Warfarin Patients: Analysis Using Data From Clinical Practice Research Datalink. Thromb. Res. 2015; 136 (2): 250-260. DOI: 10.1016/j.thromres.2015.06.007.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
